A Phase 1b/2a Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of PB-718, a GLP-1R/GCGR Dual Agonist in Subjects with Obesity

被引：0
|
作者：
Ding, Ke
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-768-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
768-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Differential efficacy of a GLP-1R/GCGR dual agonist versus a GLP-1R agonist in diet-induced obese mice
    Valdecantos, M. P.
    Ruiz, L.
    Obregon, M. J.
    Dos Santos, A.
    Bednarek, M. A.
    Grimsby, J.
    Rondinone, C.
    Valverde, A. M.
    DIABETOLOGIA, 2018, 61 : S219 - S220
  • [2] Safety and Pharmacokinetics of AZD9550, a GLP-1R/GCGR Dual Agonist, in a First-in-Human Study
    Sulentic, Petra
    Will, Sarah
    Daniels, Samuel
    Genapathy, Sivaneswary
    Naylor, Jacqueline
    Barbour, April
    Yu, Hongtao
    Boca, Simina
    Carlsson, Elin
    Gopel, Sven
    Hornigold, David
    Oldham, Stephanie
    Robertson, Darren
    Jermutus, Lutz
    Karimi, Mahssa
    Hansen, Lars
    OBESITY, 2024, 32 : 161 - 162
  • [3] The Effect of Bispecific GLP-1R/GLP-2R Agonist Compared with Dual GLP-1R/GLP-2R Agonist and Dual GLP-1R/GIPR Agonist in Diet-Induced Obesity Mouse Model
    Oh, Timothy
    Yang, Sang-In
    Roh, Jaeil
    Sung, Jee Yoon
    DIABETES, 2023, 72
  • [4] BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
    Zimmermann, Tina
    Thomas, Leo
    Baader-Pagler, Tamara
    Haebel, Peter
    Simon, Eric
    Reindl, Wolfgang
    Bajrami, Besnik
    Rist, Wolfgang
    Uphues, Ingo
    Drucker, Daniel J.
    Klein, Holger
    Santhanam, Rakesh
    Hamprecht, Dieter
    Neubauer, Heike
    Augustin, Robert
    MOLECULAR METABOLISM, 2022, 66
  • [5] Safety, Tolerability, and Pharmacokinetics of ECC5004, an Oral Small Molecule GLP-1R Agonist
    Haggag, Amina
    Pagnussat, Sandra
    Xu, Jianfeng
    Sun, Xuefeng
    Butcher, Laurie
    Pan, Xiaoliang
    Liu, Haihui
    Chen, Wen
    Xu, Jianfeng
    Zhou, Jingye
    OBESITY, 2024, 32 : 142 - 142
  • [6] Survodutide, a glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity: analysis of a placebo-controlled, randomised phase 2 trial
    Le Roux, C.
    Steen, O.
    Lucas, K. J.
    Ekinci, E., I
    Startseva, E.
    Unseld, A.
    Hennige, A. M.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [7] Differential effect of a GLP-IR/GCGR dual agonist versus a single GLP-1R agonist in the activation of BAT and browning in diet indiced obesity in mice
    Ruis Canas, L.
    Valdecantos, P.
    Konkar, A.
    Dos Santos, A.
    Bednarek, M.
    Grimsby, J.
    Rondinone, C.
    Valverde, A. M.
    DIABETOLOGIA, 2016, 59 : S49 - S49
  • [8] Effects of the Novel Dual GLP-1R/GCGR Agonist SAR425899 on Postprandial Glucose Metabolism in Overweight/Obese Subjects with Type 2 Diabetes
    Goebel, Britta
    Schiavon, Michele
    Visentin, Roberto
    Riz, Michela
    Man, Chiara Dalla
    Cobelli, Claudio
    Klabunde, Thomas
    DIABETES, 2018, 67
  • [9] Effects of the novel dual GLP-1R/GCGR agonist SAR425899 on postprandial glucose metabolism in overweight/obese subjects with type 2 diabetes
    Goebel, B.
    Schiavon, M.
    Visentin, R.
    Riz, M.
    Man, C. Dalla
    Cobelli, C.
    Klabunde, T.
    DIABETOLOGIA, 2018, 61 : S84 - S84
  • [10] A Phase 1 Single Ascending Dose Study of the Novel GLP-1R Agonist GL0034 in Subjects With Obesity
    Thennati, Rajamannar
    Burade, Vinod
    Natarajan, Muthukumar
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Panchal, Satish
    Agrawal, Sudeep
    Jandrain, Bernard
    Duvauchelle, Thierry
    Pratley, Richard
    Thorens, Bernard
    Vilsboll, Tina
    OBESITY, 2023, 31 : 284 - 284
12345